This page is dedicated to Dermatology Times' independent editorial coverage of the American Academy of Dermatology Annual Meeting.
Navigating Delusional Infestations in Dermatology
Jenny Murase, MD, said the average dermatologist manages 2-3 patients with delusional infestations every 5 years. Learn what to expect and how to manage it with empathy.
Richard Gallo, MD, PhD: Updates on Understanding the Pathophysiology of Acne
Gallo presented pearls on the pathophysiology of acne and how newer studies have changed acne treatment methodologies at AAD 2024.
2024 AAD Annual Meeting Recap: Day 3
Catch up on coverage from the third day of the 2024 American Academy of Dermatology Annual Meeting.
Late-Breaking Data: Long-Term Safety and Efficacy of Largest Prurigo Nodularis Study Ever Conducted
Shawn Kwatra, MD, presented late-breaking data at AAD 2024 on the largest prurigo nodularis and nemolizumab clinical trial, OLYMPIA.
Navigating Finances in Dermatology: Top 5 Considerations for Dermatologists
In an exclusive interview with Gary Dudzik, he shared top 5 considerations dermatology clinicians should have when choosing financial services for their practices and overall financial goals.
Late-Breaking Data: Long-Term Safety and Efficacy of Delgocitinib Cream for Chronic Hand Eczema
Melinda Gooderham, MSc, MD, FRCPC, provided insights into the significance of the DELTA 3 extension data presented at AAD 2024.
Discussing Late-Breaking INTEGUMENT-PED Data With Arcutis' Chief Medical Officer, Patrick Burnett, MD, PhD, FAAD
Burnett recently spoke with Dermatology Times to discuss the background, methods, and findings of the late-breaking INTEGUMENT-PED data, as well as its potential real-world and clinical implications.
Johnson & Johnson Reveals Promising Results for JNJ-2113 in FRONTIER 2 Study
Lloyd Miller, MD, PhD, delves into the new data demonstrating high rates of skin clearance over 52 weeks in adults with moderate to severe plaque psoriasis.
Lawrence Eichenfield, MD: Outlining Late-Breaking INTEGUMENT-PED Data for Roflumilast in Pediatric Patients
Eichenfield discusses the late-breaking data on roflumilast cream 0.05% in the pediatric patient population and its implications.
How is Artificial Intelligence Growing Up?
Joseph Zabinski, PhD, MEM, of OM1, shares insights at AAD into how artificial intelligence can mature and be a positive tool for disease detection.
Surgical Procedures to Consider for Hidradenitis Suppurativa
Maria Aleshin, MD, FAAD, presented surgical procedures for HS that can be performed in the office.
Alan Mendelsohn, MD, Shares Insights Into Congenital Ichthyosis Patient Care and the Development of TMB-001
The congenital ichthyosis session the 2024 AAD Annual Meeting covered real-world patient cases and treatments on the horizon.
Trends in Cosmeceuticals and Nutraceuticals: Exosomes and Adaptogens Take Center Stage
Discover the science behind cosmeceutical advancements and the importance of staying informed for enhanced patient care with Zoe Diana Draelos, MD.
Anticipated FDA Approval of Bimekizumab for HS: Insights From Investigator Christopher Sayed, MD
The phase 3 studies, BE HEARD I and BE HEARD II, showed significant improvements in skin pain over the 48-week period.
Adam Friedman, MD, FAAD: Exploring the Utilization of Immunomodulators as Therapeutic Interventions in Chronic Spontaneous Urticaria
In addition to recapping key highlights from his session, Friedman discusses what is new or upcoming in dermatology that most excites him.
2024 AAD Annual Meeting Recap: Day 2
Catch up on coverage from the second day of the 2024 American Academy of Dermatology Annual Meeting.
The Impact of Atopic Dermatitis on Childhood Growth: Insights from the PEDISTAD Study
The international observational study aims to understand how moderate to severe AD affects children under 12 years of age, particularly in terms of height, weight, and BMI.
Late-Breaking Data: Lutikizumab Shows Positive Results in Difficult-to-Treat HS After Failed TNF Therapy
Alexandra Kimball, MD, FAAD, reviews late-breaking data at AAD on lutikizumab for hidradenitis suppurativa.
Lessons From Boston Medical Center’s Coping Clinic
Dermatologists are able to connect pediatric patients to psychology clinicians for multidisciplinary care under one roof.
Making Psoriasis Treatment More Accessible: LITE Study Shows Home Phototherapy Success
In an AAD late-breaking research session, Joel Gelfand, MD, MSCE, FAAD, presented in-depth results of the LITE Study.
Late-Breaking Data: Upadacitinib for Vitiligo Achieves Skin Repigmentation Through Week 52
Iltefat Hamzavi, MD, reviews late-breaking data at AAD on upadacitinib as monotherapy.
Acne and Rosacea Pearls With Jim Del Rosso, DO, FAAD
The American Acne and Rosacea Society welcomed Del Rosso as its new president and he shared key takeaways from his AAD sessions.
Managing Ichthyosis in the General Dermatology Office
Christopher Bunick, MD, PhD, provides tips for the general dermatologist to treat ichthyosis and shares data on TMB-001 in development for ichthyosis.
Peter Lio, MD, FAAD: Navigating Dietary Triggers in Urticaria and Atopic Dermatitis
Lio delves into his American Academy of Dermatology Annual Meeting session, "Dietary Triggers and Modifications of Common Dermatologic Conditions: An Evidence Based Approach."
2024 AAD Annual Meeting Recap: Day 1
Catch up on coverage from the first day of the 2024 American Academy of Dermatology Annual Meeting.
Tips for Approaching Challenging Interactions and Communications With Patients
Jason S. Reichenberg, MD, MBA, FAAD, shares tips for improving interactions and communications at the 2024 AAD Annual Meeting.
HS Excision Clinical Pearls Discussed at AAD Annual Meeting
How can you improve excision care for your patients with hidradenitis suppurativa? Ashley Nicole Elsensohn, MD, MPH, FAAD, shared clinical pearls at the AAD Annual Meeting.
AAD is More Than Just a Conference
Neal Bhatia, MD, shares his insights on successfully navigating AAD and his session highlights on office politics.
Conquering the Dermatology Board Exam: Tips From Raj Chovatiya, MD, PhD
Chovatiya acknowledged the common sentiment among residents who, despite dedicating significant time to studying and working during residency, may feel unprepared.
Navigating the Path to Equity: Insights from Aletha Maybank, MD, MPH
"We cannot do health equity outside of an institution unless we figure out how to get our own house in order," the AMA leader said.